Search Videos by Topic or Participant
Browse by Series:

Available Treatment Options for RAI-Refractory DTC

Panelists: Marcia S. Brose, MD, PhD, UPenn; Naifa L. Busaidy, MD, MD Anderson;Gary L. Clayman, DMD, MD, MD Anderson; Ezra Cohen, MD, UCSD;
Published: Thursday, Jul 24, 2014
For High-Definition, Click
Surgery followed by adjuvant treatment with radioactive iodine (RAI) is a highly effective treatment for a majority of patients diagnosed with differentiated thyroid cancer (DTC). However, RAI resistance occurs in approximately 10-20% of patients, making them eligible for targeted therapy. Certain histologic subtypes suggest more advanced disease, indicating a future need for targeted therapies, notes Gary L. Clayman, DMD, MD.

Until recently, there were few therapies available for patients with RAI-refractory thyroid cancer, notes Francis P. Worden, MD. For patients presenting with RAI-refractory disease, Worden recommends a clinical trial exploring TKIs. Studies are currently exploring the TKIs lenvatinib and vandetanib as treatments in DTC. Additionally, the TKI sorafenib was approved based on results from the phase III DECISION trial.

Although TKIs are impactful in DTC, they do not cure patients of the disease. As a result, Worden's preference is to begin with a clinical trial followed by sorafenib. In off-label situations, Worden notes having used mTOR inhibitors, such as rapamycin, in the past with success.
Slider Left
Slider Right
For High-Definition, Click
Surgery followed by adjuvant treatment with radioactive iodine (RAI) is a highly effective treatment for a majority of patients diagnosed with differentiated thyroid cancer (DTC). However, RAI resistance occurs in approximately 10-20% of patients, making them eligible for targeted therapy. Certain histologic subtypes suggest more advanced disease, indicating a future need for targeted therapies, notes Gary L. Clayman, DMD, MD.

Until recently, there were few therapies available for patients with RAI-refractory thyroid cancer, notes Francis P. Worden, MD. For patients presenting with RAI-refractory disease, Worden recommends a clinical trial exploring TKIs. Studies are currently exploring the TKIs lenvatinib and vandetanib as treatments in DTC. Additionally, the TKI sorafenib was approved based on results from the phase III DECISION trial.

Although TKIs are impactful in DTC, they do not cure patients of the disease. As a result, Worden's preference is to begin with a clinical trial followed by sorafenib. In off-label situations, Worden notes having used mTOR inhibitors, such as rapamycin, in the past with success.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x